TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Suicidal Adults With Alcohol or Drug Use Problems: A New Hospital-based Treatment
Brief Summary: Individuals with alcohol or drug use problems who are hospitalized for suicide attempt are at high risk for reattempt. This treatment development study adapts a promising outpatient intervention to prevent suicide reattempt in order to administer it during hospitalization to individuals with alcohol and drug use problems, and to test the adapted intervention in a pilot randomized controlled trial.


Options:
A: Arm Label: Post Admission Cognitive Therapy (PACT); Type: EXPERIMENTAL; Interventions: Behavioral: Post Admission Cognitive Therapy (PACT) | Arm Label: Enhanced Usual Care (EUC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Post Admission Cognitive Therapy (PACT); Assigned to Arm(s): Post Admission Cognitive Therapy (PACT)
B: Arm Label: suicide attempt patient who will receive sanitory supervision; Type: OTHER; Interventions: Other: suicide attempt patient using PEPS Program | Arm Label: Suicide attempt patient who will participate to PEPS Program; Type: EXPERIMENTAL; Interventions: Other: suicide attempt patient using PEPS Program | Intervention Type: OTHER; Name: suicide attempt patient using PEPS Program; Assigned to Arm(s): Suicide attempt patient who will participate to PEPS Program, suicide attempt patient who will receive sanitory supervision
C: Arm Label: brief intervention to prevent suicide attempt; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention to prevent suicide attempt | Arm Label: standard of care; Type: OTHER; Interventions: Behavioral: Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Brief intervention to prevent suicide attempt; Assigned to Arm(s): brief intervention to prevent suicide attempt | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual; Assigned to Arm(s): standard of care
D: Arm Label: F-SPS Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: F-SPS+UC | Arm Label: Enhanced Usual Care (EUC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: EUC | Intervention Type: BEHAVIORAL; Name: F-SPS+UC; Assigned to Arm(s): F-SPS Intervention | Intervention Type: BEHAVIORAL; Name: EUC; Assigned to Arm(s): Enhanced Usual Care (EUC)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Suicidal Adults With Alcohol or Drug Use Problems: A New Hospital-based Treatment
Brief Summary: Individuals with alcohol or drug use problems who are hospitalized for suicide attempt are at high risk for reattempt. This treatment development study adapts a promising outpatient intervention to prevent suicide reattempt in order to administer it during hospitalization to individuals with alcohol and drug use problems, and to test the adapted intervention in a pilot randomized controlled trial.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: APSOM vs Control | Arm Label: APSOM; Type: OTHER; Interventions: Other: APSOM vs Control | Intervention Type: OTHER; Name: APSOM vs Control; Assigned to Arm(s): APSOM, Control
B: Arm Label: CARMS therapy + TAU; Type: EXPERIMENTAL; Interventions: Other: Cognitive AppRoaches to coMbatting Suicidality (CARMS) | Arm Label: TAU; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cognitive AppRoaches to coMbatting Suicidality (CARMS); Assigned to Arm(s): CARMS therapy + TAU
C: Arm Label: Intervention Group ASSIP; Type: EXPERIMENTAL; Interventions: Behavioral: Attempted Suicide Short Intervention Program (ASSIP) | Arm Label: Control Group CG; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Group (CG) | Intervention Type: BEHAVIORAL; Name: Attempted Suicide Short Intervention Program (ASSIP); Assigned to Arm(s): Intervention Group ASSIP | Intervention Type: BEHAVIORAL; Name: Control Group (CG); Assigned to Arm(s): Control Group CG
D: Arm Label: brief intervention to prevent suicide attempt; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention to prevent suicide attempt | Arm Label: standard of care; Type: OTHER; Interventions: Behavioral: Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Brief intervention to prevent suicide attempt; Assigned to Arm(s): brief intervention to prevent suicide attempt | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual; Assigned to Arm(s): standard of care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors.
Brief Summary: The purpose of this study is to determine whether Medroxyprogesterone Acetate (MPA) administration in follicular phase prevents premature luteinization with equal efficiency as GnRH antagonists and otains similar clinical results in oocyte donation.


Options:
A: Arm Label: Freeze-all protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Freeze-all protocol | Arm Label: Fresh transfer protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh transfer protocol | Intervention Type: PROCEDURE; Name: Freeze-all protocol; Assigned to Arm(s): Freeze-all protocol | Intervention Type: PROCEDURE; Name: Fresh transfer protocol; Assigned to Arm(s): Fresh transfer protocol
B: Arm Label: Progevera; Type: EXPERIMENTAL; Interventions: Drug: Progevera | Arm Label: Orgalutran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Orgalutran | Intervention Type: DRUG; Name: Progevera; Assigned to Arm(s): Progevera | Intervention Type: DRUG; Name: Orgalutran; Assigned to Arm(s): Orgalutran
C: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
D: Arm Label: Provera; Type: EXPERIMENTAL; Interventions: Drug: Provera 10 mg. | Arm Label: Orgalutrán Ganirelix (GnRH antagonist); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ganirelix (GnRH antagonist) | Intervention Type: DRUG; Name: Provera 10 mg.; Assigned to Arm(s): Provera | Intervention Type: DRUG; Name: Ganirelix (GnRH antagonist); Assigned to Arm(s): Orgalutrán Ganirelix (GnRH antagonist)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects on Oxidative Stress and Platelet Activation of Traditional Cigarettes, E-cigarettes and IQOS Cigarettes: A Randomized in Vivo Study.
Brief Summary: Electronic cigarettes (E-cigarettes) and new heat-not-burn tobacco products such as IQOS®, an electronic device that heats a cigarette-like stick without combustion, are a modern and technological surrogate of traditional tobacco cigarettes (T-cigarettes), that are entering in the commercial market. While the negative effects of the traditional cigarette are well known, little data are reported in scientific literature on the risks on the health by these new smoking devices. Endothelial dysfunction evaluated by flow-mediated dilatation (FMD), oxidative stress and platelet activation have been recognized as a hallmark of preclinical systemic atherosclerosis and as a useful marker to stratify the risk of cardiovascular disease in patients at risk or with established clinically significant atherosclerosis. Since no data are reported about the effects of these new smoking device on oxidative stress, platelet activation and FMD, the investigators designed a human study assessing if these new smoking devices have effects on healthy smokers.


Options:
A: Arm Label: E-Cigarette; Type: EXPERIMENTAL; Interventions: Other: E-Cigarette Vs. Smoking as Usual | Arm Label: Assessment Only; Type: ACTIVE_COMPARATOR; Interventions: Other: E-Cigarette Vs. Smoking as Usual | Intervention Type: OTHER; Name: E-Cigarette Vs. Smoking as Usual; Assigned to Arm(s): Assessment Only, E-Cigarette
B: Arm Label: Traditional cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Arm Label: Electronic cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Arm Label: Heat-not-burn tobacco products (IQOS); Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Intervention Type: BEHAVIORAL; Name: Smoke; Assigned to Arm(s): Electronic cigarette, Heat-not-burn tobacco products (IQOS), Traditional cigarette
C: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
D: Arm Label: E-cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Traditional cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Mixed group; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects on Oxidative Stress and Platelet Activation of Traditional Cigarettes, E-cigarettes and IQOS Cigarettes: A Randomized in Vivo Study.
Brief Summary: Electronic cigarettes (E-cigarettes) and new heat-not-burn tobacco products such as IQOS®, an electronic device that heats a cigarette-like stick without combustion, are a modern and technological surrogate of traditional tobacco cigarettes (T-cigarettes), that are entering in the commercial market. While the negative effects of the traditional cigarette are well known, little data are reported in scientific literature on the risks on the health by these new smoking devices. Endothelial dysfunction evaluated by flow-mediated dilatation (FMD), oxidative stress and platelet activation have been recognized as a hallmark of preclinical systemic atherosclerosis and as a useful marker to stratify the risk of cardiovascular disease in patients at risk or with established clinically significant atherosclerosis. Since no data are reported about the effects of these new smoking device on oxidative stress, platelet activation and FMD, the investigators designed a human study assessing if these new smoking devices have effects on healthy smokers.


Options:
A: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
B: Arm Label: Electronic cigarette with or without nicotine; Type: ACTIVE_COMPARATOR; Interventions: Other: Electronic cigarette | Arm Label: Smoker control; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional cigarette | Intervention Type: OTHER; Name: Electronic cigarette; Assigned to Arm(s): Electronic cigarette with or without nicotine | Intervention Type: OTHER; Name: Conventional cigarette; Assigned to Arm(s): Smoker control
C: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
D: Arm Label: Traditional cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Arm Label: Electronic cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Arm Label: Heat-not-burn tobacco products (IQOS); Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Intervention Type: BEHAVIORAL; Name: Smoke; Assigned to Arm(s): Electronic cigarette, Heat-not-burn tobacco products (IQOS), Traditional cigarette

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects on Oxidative Stress and Platelet Activation of Traditional Cigarettes, E-cigarettes and IQOS Cigarettes: A Randomized in Vivo Study.
Brief Summary: Electronic cigarettes (E-cigarettes) and new heat-not-burn tobacco products such as IQOS®, an electronic device that heats a cigarette-like stick without combustion, are a modern and technological surrogate of traditional tobacco cigarettes (T-cigarettes), that are entering in the commercial market. While the negative effects of the traditional cigarette are well known, little data are reported in scientific literature on the risks on the health by these new smoking devices. Endothelial dysfunction evaluated by flow-mediated dilatation (FMD), oxidative stress and platelet activation have been recognized as a hallmark of preclinical systemic atherosclerosis and as a useful marker to stratify the risk of cardiovascular disease in patients at risk or with established clinically significant atherosclerosis. Since no data are reported about the effects of these new smoking device on oxidative stress, platelet activation and FMD, the investigators designed a human study assessing if these new smoking devices have effects on healthy smokers.


Options:
A: Arm Label: E-Cigarette 7.2 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: E-Cigarette 7.2 mg nicotine | Intervention Type: DEVICE; Name: E-Cigarette 7.2 mg nicotine; Assigned to Arm(s): E-Cigarette 7.2 mg nicotine
B: Arm Label: Standard Arm (Arm A); Type: ACTIVE_COMPARATOR; Interventions: Other: TOBACCO CIGARETTES | Arm Label: Intervention Arm (Arm B); Type: ACTIVE_COMPARATOR; Interventions: Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS) | Intervention Type: OTHER; Name: TOBACCO CIGARETTES; Assigned to Arm(s): Standard Arm (Arm A) | Intervention Type: OTHER; Name: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS); Assigned to Arm(s): Intervention Arm (Arm B)
C: Arm Label: E-Cigarette; Type: EXPERIMENTAL; Interventions: Other: E-Cigarette Vs. Smoking as Usual | Arm Label: Assessment Only; Type: ACTIVE_COMPARATOR; Interventions: Other: E-Cigarette Vs. Smoking as Usual | Intervention Type: OTHER; Name: E-Cigarette Vs. Smoking as Usual; Assigned to Arm(s): Assessment Only, E-Cigarette
D: Arm Label: Traditional cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Arm Label: Electronic cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Arm Label: Heat-not-burn tobacco products (IQOS); Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Intervention Type: BEHAVIORAL; Name: Smoke; Assigned to Arm(s): Electronic cigarette, Heat-not-burn tobacco products (IQOS), Traditional cigarette

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Multicenter, Prospective, Randomized, Double Blind, Placebocontrolled Study to Reduce Incidence of Pre-dialysis Hyperkalemia With Sodium Zirconium Cyclosilicate (DIALIZE)
Brief Summary: The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.


Options:
A: Arm Label: Group 1 - Dosing Without Food; Type: EXPERIMENTAL; Interventions: Drug: patiromer | Arm Label: Group 2 - Dosing With Food; Type: ACTIVE_COMPARATOR; Interventions: Drug: patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Group 1 - Dosing Without Food, Group 2 - Dosing With Food
B: Arm Label: Patiromer; Type: ACTIVE_COMPARATOR; Interventions: Drug: Patiromer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Patiromer; Assigned to Arm(s): Patiromer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sodium Zirconium Cyclosilicate (ZS); Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS); Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS)
D: Arm Label: Sodium zirconium cyclosilicate 10 g three times daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Placebo once daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sodium zirconium cyclosilicate 5 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Sodium zirconium cyclosilicate 10 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Sodium zirconium cyclosilicate 15 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Intervention Type: DRUG; Name: Sodium zirconium cyclosilicate; Assigned to Arm(s): Sodium zirconium cyclosilicate 10 g once daily, Sodium zirconium cyclosilicate 10 g three times daily, Sodium zirconium cyclosilicate 15 g once daily, Sodium zirconium cyclosilicate 5 g once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo once daily

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients
Brief Summary: Recent advances in molecular diagnostics of tuberculosis, especially the GeneXpert Mycobacterium tuberculosis/Rifampicin test have reduced the time to diagnose Rifampicin Resistant Tuberculosis (RR-TB) but only rifampicin resistance is diagnosed, leading to presumptive diagnosis of resistance to isoniazid and maybe other drugs. Thus in low and middle income countries, most drug sensitivity testing relies on phenotypic drug resistance testing, which takes up to 4 months. In addition, currently, culture on monthly sputum samples is recommended by the World Health Organization for follow-up of Rifampicin Resistant Tuberculosis patients under treatment. Unfortunately, culture is often not locally available and samples need to be transported from field to culture laboratories. The associated transport delays lead to high rates of contamination and false negative culture, particularly in laboratories in low resource settings. Many gaps for the diagnosis and management of RR-TB patients still need to be addressed and the DIAMA project (DIAgnostics for Multidrug resistant tuberculosis in Africa) study aims to address some of them.


Options:
A: Arm Label: TB case detection Group; Type: N/A; Interventions: Device: Cepheid Gene Xpert MTB/XDR | Arm Label: RIF-resistance MTB Group; Type: N/A; Interventions: Device: Cepheid Gene Xpert MTB/XDR | Intervention Type: DEVICE; Name: Cepheid Gene Xpert MTB/XDR; Assigned to Arm(s): RIF-resistance MTB Group, TB case detection Group
B: Arm Label: Rifampicin resistant and susceptible patients; Type: N/A; Interventions: Diagnostic Test: Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line | Arm Label: Rifampicin resistant patients; Type: N/A; Interventions: Diagnostic Test: Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis | Intervention Type: DIAGNOSTIC_TEST; Name: Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line; Assigned to Arm(s): Rifampicin resistant and susceptible patients | Intervention Type: DIAGNOSTIC_TEST; Name: Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis; Assigned to Arm(s): Rifampicin resistant patients
C: Arm Label: Centralised Xpert®Ultra testing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Xpert Ultra Point of Care testing; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Xpert Ultra Point of Care testing | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert Ultra Point of Care testing; Assigned to Arm(s): Xpert Ultra Point of Care testing
D: Arm Label: Case Detection Group; Type: N/A; Interventions: Diagnostic Test: Truenat MTB | Arm Label: Drug Resistant TB Group; Type: N/A; Interventions: Diagnostic Test: Truenat MTB | Intervention Type: DIAGNOSTIC_TEST; Name: Truenat MTB; Assigned to Arm(s): Case Detection Group, Drug Resistant TB Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Two Different Treatments for Lower Pore Renal Stone: Microperc Vs FURS
Brief Summary: This is a prospect, randomized control trial to evaluate merits between microperc and FURS for lower pole renal stone


Options:
A: Arm Label: RIRS (retrograde intrarenal surgery); Type: EXPERIMENTAL; Interventions: Procedure: RIRS, Device: Rigid and flexible ureteroscope, Device: Holmium laser, Device: Basket for fragment removal, Procedure: General or spinal anesthesia, Device: X-ray | Arm Label: ESWL (extracorporeal shockwaves lithotripsy); Type: EXPERIMENTAL; Interventions: Procedure: ESWL, Device: Lithotripter, Drug: Intravenous pain medication, Device: X-ray, Device: Ultrasound | Intervention Type: PROCEDURE; Name: RIRS; Assigned to Arm(s): RIRS (retrograde intrarenal surgery) | Intervention Type: PROCEDURE; Name: ESWL; Assigned to Arm(s): ESWL (extracorporeal shockwaves lithotripsy) | Intervention Type: DEVICE; Name: Rigid and flexible ureteroscope; Assigned to Arm(s): RIRS (retrograde intrarenal surgery) | Intervention Type: DEVICE; Name: Lithotripter; Assigned to Arm(s): ESWL (extracorporeal shockwaves lithotripsy) | Intervention Type: DEVICE; Name: Holmium laser; Assigned to Arm(s): RIRS (retrograde intrarenal surgery) | Intervention Type: DEVICE; Name: Basket for fragment removal; Assigned to Arm(s): RIRS (retrograde intrarenal surgery) | Intervention Type: PROCEDURE; Name: General or spinal anesthesia; Assigned to Arm(s): RIRS (retrograde intrarenal surgery) | Intervention Type: DRUG; Name: Intravenous pain medication; Assigned to Arm(s): ESWL (extracorporeal shockwaves lithotripsy) | Intervention Type: DEVICE; Name: X-ray; Assigned to Arm(s): ESWL (extracorporeal shockwaves lithotripsy), RIRS (retrograde intrarenal surgery) | Intervention Type: DEVICE; Name: Ultrasound; Assigned to Arm(s): ESWL (extracorporeal shockwaves lithotripsy)
B: Arm Label: Microperc surgery; Type: EXPERIMENTAL; Interventions: Procedure: Microperc surgery | Arm Label: FURS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: FURS | Intervention Type: PROCEDURE; Name: Microperc surgery; Assigned to Arm(s): Microperc surgery | Intervention Type: PROCEDURE; Name: FURS; Assigned to Arm(s): FURS
C: Arm Label: PCNL Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PCNL | Arm Label: mini-PCNL Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: mini-PCNL | Arm Label: RIRS Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RIRS | Intervention Type: PROCEDURE; Name: PCNL; Assigned to Arm(s): PCNL Group | Intervention Type: PROCEDURE; Name: mini-PCNL; Assigned to Arm(s): mini-PCNL Group | Intervention Type: PROCEDURE; Name: RIRS; Assigned to Arm(s): RIRS Group
D: Arm Label: RIRS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Retrograde intrarenal surgery | Arm Label: PCNL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous nephrolithotomy | Intervention Type: PROCEDURE; Name: Percutaneous nephrolithotomy; Assigned to Arm(s): PCNL | Intervention Type: PROCEDURE; Name: Retrograde intrarenal surgery; Assigned to Arm(s): RIRS

Answer: B